MAb 151-45-4 (ATCC® HB-12682)

Organism: Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)  /  Cell Type: hybridoma:lymphocyte B lymphocyte  / 

Permits and Restrictions

View Permits

Organism Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)
Cell Type hybridoma:lymphocyte B lymphocyte
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 1
Strain

Strain:  BALB/c (B cell); BALB/c  (myeloma)

Applications
The antibody can be used for screening drugs for metabolism by cytochrome P450 2A6, and in methods of measuring p450 2A6 levels in individuals relative to p450 2A6 levels in a control population [U.S. Pat.
MAb 151-45-4 (ATCC HB-12682) specifically binds human cytochrome P450 2A6 [U.S. Pat.
It inhibits enzyme activity of human cytochrome P450 2A6 and lacks specific binding to other human cytochromes P450 [U.S. Pat.
Storage Conditions liquid nitrogen vapor phase
Derivation
Animals were immunized with baculovirus-expressed human cytochrome P450 2A6 [U.S. Pat. 6,323,325]. Spleen cells were fused NS1 myeloma cells. MAb 151-45-4 (ATCC HB-12682) specifically binds human cytochrome P450 2A6 [U.S. Pat. 6,323,325]. It inhibits enzyme activity of human cytochrome P450 2A6 and lacks specific binding to other human cytochromes P450 [U.S. Pat. 6,323,325]. The antibody can be used for screening drugs for metabolism by cytochrome P450 2A6, and in methods of measuring p450 2A6 levels in individuals relative to p450 2A6 levels in a control population [U.S. Pat. 6,323,325].
Comments
Animals were immunized with baculovirus-expressed human cytochrome P450 2A6 [U.S. Pat. 6,323,325]. Spleen cells were fused NS1 myeloma cells. MAb 151-45-4 (ATCC HB-12682) specifically binds human cytochrome P450 2A6 [U.S. Pat. 6,323,325]. It inhibits enzyme activity of human cytochrome P450 2A6 and lacks specific binding to other human cytochromes P450 [U.S. Pat. 6,323,325]. The antibody can be used for screening drugs for metabolism by cytochrome P450 2A6, and in methods of measuring p450 2A6 levels in individuals relative to p450 2A6 levels in a control population [U.S. Pat. 6,323,325].
Complete Growth Medium RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, 1.0 mM sodium pyruvate and supplemented with 5% Origen Hybridoma Cloning Factor and 15% fetal bovine serum
Subculturing
Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 X 10(5) viable cells/ml.
Interval: Maintain cell density between 2 X 10(5) and 1 X 10(6) viable cells/ml.
Medium Renewal: Every 2 to 3 days
Cryopreservation
Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Culture Conditions
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Isotype IgG1 kappa
Name of Depositor The United States of America
References

Gelboin HV, Gonzalez FJ. Agents that bind to and inhibit human cytochrome P450 2A6. US Patent 6,323,325 dated Nov 27 2001

Sai Y, et al. An inhibitory monoclonal antibody to human cytochrome P450 2A6 defines its role in the metabolism of coumarin, 7-ethoxycoumarin and 4-nitroanisole in human liver. Pharmacogenetics 9: 229-237, 1999. PubMed: 10376770

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
References

Gelboin HV, Gonzalez FJ. Agents that bind to and inhibit human cytochrome P450 2A6. US Patent 6,323,325 dated Nov 27 2001

Sai Y, et al. An inhibitory monoclonal antibody to human cytochrome P450 2A6 defines its role in the metabolism of coumarin, 7-ethoxycoumarin and 4-nitroanisole in human liver. Pharmacogenetics 9: 229-237, 1999. PubMed: 10376770